A dilemma in ALS, the first MASH drug, & why gene therapy is hard

What happens when an approved drug doesn’t work? Why don’t patients want gene therapy? And is MASH still a big deal?
We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Bioethicist Holly Fernandez Lynch joins us to discuss the case of Amylyx Pharmaceuticals’ treatment for ALS and what its failure means for drug development. We also discuss the latest news in the life sciences, including a tepid reception for gene therapies, the future of CAR-T cancer treatment, and the first approved medicine for a prevalent liver disease.
More from STAT:
Become a subscriber: www.statnews.com/stat-plus/
Watch Full Episodes: / @statnews
Newsletters: www.statnews.com/signup/
STAT events: www.statnews.com/stat-events/
Facebook: / statnews
Twitter: / statnews
Instagram: / statnews
Flipboard: rb.gy/3xnsxr
STAT Reports: rb.gy/rexfwj
STAT eBooks: rb.gy/eme3h5
ABOUT STAT:
Founded in 2015, STAT is a global digital media brand that focuses on delivering fast, deep, and tough-minded journalism about the life sciences industries to over six million monthly site visitors and an additional 20 million readers on the Apple News app. STAT takes you inside academic labs, biotech boardrooms, and political backrooms, casting a critical eye on scientific discoveries, scrutinizing corporate strategies, and chronicling the roiling battles for talent, money, and market share. With an award-winning newsroom, STAT provides indispensable insights and exclusive stories on the technologies, personalities, power brokers, and political forces driving massive changes in the life sciences industry - and a revolution in human health.